Advances in An+coagula+on
|
|
- Melissa Virginia Dalton
- 8 years ago
- Views:
Transcription
1 Advances in An+coagula+on Laurajo Ryan PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Aus+n College of Pharmacy UTHSCSA School of Medicine Pharmcotherapy Research Educa+on Center
2 Accredita+on & Disclosures Advances in An+coagula+on is accredited for 1.5 contact hours by: ACPE for pharmacists, ACPE L01- P Technicians, ACPE L01- T Laurajo Ryan has not disclosed any financial or conflicts of interest in rela+on to this program
3 Learning Objec+ves By the end of this session, the par+cipant should be able to: Review recent developments in an+coagula+on therapy List the key prescribing points and safety concerns for new an+coagulants Iden+fy op+ons for reversal of new an+coagulants Discuss transi+on between new an+coagulants
4 Thromboembolisms: The Problem United States Precise numbers unknown Es+mated at K/year 1-2/1000 1/100 >80 YOA Mortality K/year 25% of pa+ents with PE present with sudden death ½ with DVT Long- term complica+ons 10 years ~33% recurrence CDC: hcp://
5 An+coagulan+on Does newer = becer?
6 An+coagula+on Cascade Adapted from: Ryan. In Acridge, Miller, Moote, Ryan eds. Internal Medicine: A Guide to Clinical Therapeu+cs. McGraw- Hill 2013
7 An+coagulants Warfarin (Coumadin ) Inhibits clokng factors Heparins II, VII, IX, X Proteins C & S Unfrac+onated (UFH) Factor IIa Xa Low Molecular Weight (LMWH) Factor Xa >>> IIa Factor Xa inhibitors Fondaparinux (Arixtra ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Direct thrombin inhibitors Argatroban Bivalirudin (Angiomax ) Dabigatran (Pradaxa )
8 An+coagulant Site of Ac+on Adapted from: Ryan. In Acridge, Miller, Moote, Ryan eds. Internal Medicine: A Guide to Clinical Therapeu+cs. McGraw- Hill 2013
9 An+coagulants Does newer = becer?
10 VITAMIN K ANTAGONIST
11 Warfarin Pros Many years of clinical data Ability to monitor effect Reliable reversal agent Vitamin K Cheap Once daily dosing
12 Warfarin Cons Inferior bleeding profile in some studies Delay in an+coagula+on ac+on Monitoring requirements Drug/diet interac+ons Gene+c variability
13 Risks & Reversibility Bleeding risk with INR GI tract Cerebral hemorrhage Elderly at higher risk An+dote Vitamin K Fresh frozen plasma FFP Prothrombin complex concentrate (II, VII, IX, X) PCC Recombinant factor VIIa Chest 2012;141(Suppl 2):e152S
14 FACTOR Xa INHIBITORS
15 An+coagulant Site of Ac+on Adapted from: Ryan. In Acridge, Miller, Moote, Ryan eds. Internal Medicine: A Guide to Clinical Therapeu+cs. McGraw- Hill 2013
16 Rivaroxaban (Xarelto ) Oral Xa inhibitor Reversible Renally cleared Must adjust Doses 15mg/day; take with food t½ ~ 10 hours DVT treatment 15mg BID X3 weeks Then 20mg QD Contraindicated <30mL/min Non- valvular afib 20mg QD CrCl 30 50mL/min 15mg QD Crcl <15mL/min Contraindicated Post- op PPX (hip/knee) 10mg QD Crcl <30mL/min Contraindicated
17 Rivaroxaban No specific an+dote Not dialyzable High protein binding Life- threatening bleed Packed RBC Aggressive bleeding management 4- factor PCC Drug interac+ons 3A4 metabolism risk of bleed An+coagulants NSAIDs An+- platelet agents Thromboly+cs 3A4 inhibitors effects Strong 3A4 inducers P- glycoprotein inducers St. Johns wort
18 Rivaroxaban Pros Once daily dosing No monitoring VTE treatment Does not require bridging with parenteral agent Cons Renally eliminated Short t½ Non- compliance issues Non- inferior to warfarin for afib More bleeding in general VTE prophylaxis popula+on Limited reversal op+ons No widely available monitoring Drug interac+ons Expensive ~$300 for 30 day supply
19 Apixaban (Eliquis ) Oral Xa inhibitor Reversible t½ ~ 8-15 hours DVT treatment 10mg BID X7 days Then 5mg BID 2.5mg BID azer 6 months Non- valvular atrial fibrilla+on 5mg BID 2.5mg BID if any 2: Scr 1.5mg/dL Age 80 Weight 60kg Post- op PPX (hip/knee) 2.5mg BID
20 Apixaban No specific an+dote Not dialyzable High protein binding Life- threatening bleed Packed RBC Aggressive bleeding management Prothrombin complex concentrate (PCC) Drug interac+ons 3A4 metabolism risk of bleed An+coagulants NSAIDs An+- platelet agents Thromboly+cs 3A4 inhibitors effects 3A4 inducers P- glycoprotein inducers St. Johns wort
21 Apixaban Pros Oral agent No monitoring No need for bridging therapy Data in afib >>> vs. warfarin Lowest compara+ve bleeding risk of NOACs Cons Dose- adjustment rubric No monitoring No specific an+dote Short t½ Non- compliance risks More GI bleeds vs. warfarin No reliable reversal agent Licle data available Cost
22 Edoxaban (Savaysa ) Oral Xa inhibitor Reversible t½ ~ 8-15 hours DVT treatment 60mg QD azer 5-10 days parenteral tx 60kg = 30mg If using P- gp inhibitor reduce to 30mg QD Renally eliminated Do NOT use if CrCl >95mL/min CrCl 15-50mL/min 30mg QD Avoid if CrCl <15mL/min
23 Edoxaban Pros Oral agent No monitoring No need for bridging therapy Cons Dose- adjustment for drug interac+ons No monitoring No specific an+dote No reliable reversal agent Licle data available Cost
24 DIRECT THROMBIN INHIBITORS
25 An+coagulant Site of Ac+on Adapted from: Ryan. In Acridge, Miller, Moote, Ryan eds. Internal Medicine: A Guide to Clinical Therapeu+cs. McGraw- Hill 2013
26 Direct Thrombin Inhibitors Inhibit thrombin Circula+ng & fibrin- bound Do not need an+- thrombin as co- factor HIT No cross- reac+vity with heparin products No specific an+dote
27 Dabigatran (Pradaxa ) Oral reversible thrombin inhibitor RELY trial compared to warfarin in afib Decreased stroke risk Similar overall bleeding No superiority if good warfarin control 2X é GI bleed» Bioavailability? ê risk intracranial bleed Non- valvular atrial fibrilla+on 150mg BID Renal clearance 75mg BID ClCr 15 30mL/min Contraindicated <15mL/min DVT/PE 150mg BID Azer parenteral an+coagulant
28 Dabigatran Hygroscopic capsules Dispense/store in original packaging Discard 4 months azer opening Do not break or open capsule é bioavailability t½ ~ hours Adverse effects Bleeding GI distress No an+dote May be reversed by prothrombin complex concentrate (PCC) Provides factor II Removed by hemodialysis
29 Dabigatran Drug interac+ons P- glycoprotein inducers ê dabigatran concentra+ons Avoid combina+on with strong inducers Rifampin Elderly Increased bleeding risk; no specific dosing guidelines Disease- related concerns Variability in hepa+c impairment Use in advanced liver disease not recommended Renal dysfunc+on Concentra+on é up to 3X with moderate ê func+on American College of Chest Physicians (ACCP)*» Clcr <30mL/min contraindicated
30 Dabigatran In the News BMJ inves+ga+on States recommenda+ons for dabigatran may be flawed Manufacturers withheld informa+on showing drug concentra+on monitoring may improved safety Op+mally used (= +trated) dabigatran has the poten+al to provide pa+ents an even becer efficacy and safety profile than fixed dose dabigatran and also a becer safety and efficacy profile than a matched warfarin group. BMJ 2014;349
31 Dabigatran Pros Oral agent No monitoring More effec+ve vs. warfarin for stroke & VTE No lifestyle limita+ons Cons No monitoring* Drug interac+ons with p- glycoprotein inducers Renally eliminated No specific an+dote Increased GI bleeding Short t½ Non- compliance risks BID dosing Capsule instability Cost
32 REVERSAL OPTIONS
33 Current Reversal Op+ons Agent Vitamin K Protamine Sulfate Fresh Frozen Plasma (FFP) Comments Cheapest agent, most data; only effec+ve against warfarin Binds to heparin; cheap Must be thawed, high volume; contains all clokng factors Prothrombin Complex Concentrates (PCC) Recombinant ac+vated factor VII *per977 *andexanet alfa (Annexa- R) *idracizumab Profilnine /Bebulin - - ac+vated factors II/IX/X $$ Kcentra /Feiba - - non- ac+vated factors II/IX/X + ac+vated fvii $$ $$$$$$$ Directly combines with NOACs, LMWH, UFH without binding coagula+on factors IV modified Xa molecule acts as a decoy; targets & sequesters Xa inhibitors (rivaroxaban, apixaban, edoxaban) IV an+body fragment binds & inac+vates dabigatran *currently in clinical trials
34 NOAC DOSING & CONVERSION
35 Typical Dosing Regimens Factor Xa Inhibitors Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Dabigatran (Pradaxa ) Afib: 20mg QDay VTE: 15mg BID X 21days; then 20mg QDay DVT PPX: 10mg QDay up to 35 days post- op Afib: 5mg BID VTE: 10mg BID X 7days; 5mg BID X6 months; 2.5mg BID if con+nuing therapy DVT PPX: 2.5mg BID up to 35 days post- op Afib: 60mg QDay VTE: 60mg QDay azer 5-10 days parenteral tx Direct Thrombin Inhibitor Afib: 150mg BID VTE: 150mg BID azer 5-10 days parenteral tx
36 Conversions.to NOAC. From warfarin Start NOAC when INR < 2 Edoxaban when INR 2.5 From SQ an+coagulant Start NOAC 2 hours before the next scheduled SC injec+on At scheduled +me for edoxaban From IV an+coagulant Start NOAC when infusion is stopped 4 hours azer DC for edoxaban from NOAC to Parenteral an+coagulant Wait hours azer last NOAC dose Warfarin CrCl > 50 ml/min: Start warfarin 3 days before NOAC D/C CrCl ml/min: Start warfarin 2 days before NOAC D/C Apixaban affects INR Ini+ate warfarin AND parenteral agent 24 azer DC Edoxaban drop dose to 15mg & ini+ate warfarin; DC when INR stable 2
37 NOAC Periopera+ve Management Bleed Risk Examples Stopping strategy Re- Start Strategy High Risk Cancer surgery Major ortho surgery Cardiac/spinal/cranial surgery Surgery > 45 min Renal biopsy CrCl >50mL/min; last dose 3 days before procedure CrCl 30-50mL/min; last dose 4 days before procedure Restart 48-72h postop Low Risk Minor dental procedure Lymph node biopsy Shoulder/hand surgery Lap Cholecystectomy Colonoscopy CrCl >50mL/min; last dose 2 days before procedure CrCl 30-50mL/min; last dose 3 days before procedure Restart 24h postop
38 Oral An+coagulant Summary Drug Dosing Monitor? Dose adjust? Drug intx? Specific anhdote? Warfarin PO, daily INR, food Yes $ Cost Rivaroxaban PO, daily* No Renal No $$$ Apixaban PO, BID No Renal, wt No $$$ Edoxaban PO, daily No Renal* No $$$ Dabigatran PO, BID No Renal No* $$$
39 NOAC Summary Pros No need for bridging with injectables for some NOACs Less lifestyle intrusions compared to warfarin Less bleeding compared to warfarin? Cons $$$$ Limited reversal agents Mul+ple day dosing Limited clinical informa+on Drug interac+ons exist, but <<< vs. warfarin
40 NOAC Summary Many new an+coagulants have entered or will enter the market in the future decade A clear understanding of pros/cons of NOACs required for safe use Affordable reversal strategies s+ll needed for NOACs Warfarin s+ll viable op+on for many pa+ents, but use is decreasing
Comparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationManagement of invasive procedures and bleeding compica5ons in pa5ents on NOACs
Management of invasive procedures and bleeding compica5ons in pa5ents on NOACs Michiel Coppens MD PhD Internist- Vascular Medicine Academic Medical Center, Amsterdam, The Netherlands McMaster University,
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationCONTEMPORARY REVERSAL OF ANTICOAGULATION
CONTEMPORARY REVERSAL OF ANTICOAGULATION Michael S. McHale, M.D., F.A.C.P. Avera Medical Group Hematology & Oncology Medications Coumadin / Warfarin Unfractionated Heparin Low Molecular Weight Heparin
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationClinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationDisclosures. Objective (NRHS) Self Assessment #2
Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationThe New An)coagulants: Prac)cal Applica)on. Ma8hew Rondina, M.D. Department of Internal Medicine University of Utah Medical Center
The New An)coagulants: Prac)cal Applica)on Ma8hew Rondina, M.D. Department of Internal Medicine University of Utah Medical Center Learning Objec)ves 1. Understand the prac)cal considera)ons and poten)al
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationAdvanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More informationTimeline: FDA approval of NOACs. FDA-approved oral anticoagulants. FDA-approved oral anticoagulants. Stroke risk reductions: afib RCTs 4/8/2016
Christina York, PharmD, BCPS Pharmacology Conference April 2016 Objectives Compare current FDA-approved oral anticoagulants Understand practical issues that arise with novel oral anticoagulants Consider
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationHome treatment of VTE
Home treatment of VTE Prof. Adel El-Etriby Ain-Shams University Venous Thromboembolism (VTE): The DVT and PE Continuum Migration Embolus Thrombus VTE refers to a continuum of disease that begins with DVT
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationIt s a. of Anticoagulation. Objectives
It s a New World of Anticoagulation LAURA B. RICHARDSON, PHARMD, BCPS-CV CLINICAL PHARMACIST ABBOTT NORTHWESTERN HOSPITAL Objectives Understand the key differences between the oral anticoagulants t Become
More informationAn#coagulant Choices in Renal Impairment
An#coagulant Choices in Renal Impairment Karen Shalansky, Pharm.D. Pharmacotherapeu#c Specialist, Nephrology Vancouver General Hospital Clinical Professor Faculty of Pharmaceu#cal Sciences, UBC karen.shalansky@vch.ca
More informationHow to Manage Warfarin Management
How to Manage Warfarin Management Katie McClendon, PharmD, BCPS University of Mississippi School of Pharmacy AS MANDATED BY ACCME SPEAKERS ARE ASKED TO DISCLOSE ANY REAL OR APPARENT CONFLICT RELATED TO
More informationOMG my pa*ent is bleeding pa*ent is on NOACs!! Bryan Poon, PharmD Clinical Quality Manager UT Southwestern Medical Center at Dallas
OMG my pa*ent is bleeding pa*ent is on NOACs!! Bryan Poon, PharmD Clinical Quality Manager UT Southwestern Medical Center at Dallas Disclosure Financial disclosure: NONE Off label drug use disclosure:
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationLow Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationTraveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationSAVAYSA (edoxaban) U.S. Opportunity
SAVAYSA (edoxaban) U.S. Opportunity February 17, 2015 Ken Keller President, U.S. Commercial DSI, Inc. Key Discussion Points Daiichi Sankyo, Inc. (DSI) in the U.S. SAVAYSA (edoxaban) U.S. Indication NOAC
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More information